Article Information
- December 22, 2021.
Article Versions
- Version 1 (December 21, 2021 - 12:31).
- You are currently viewing Version 2 of this article (December 22, 2021 - 07:01).
- View Version 3, the most recent version of this article.
REVISION SUMMARY
This version of the manuscript has been revised to update the following. (1) the duplicate version of the figure has been removed; (2) the 95% CI reported in the abstract for the VE against infection with Omicron after completion of a primary 2-dose mRNA-1273 vaccination series has been corrected to show a lower limit of minus 69.9, rather than positive 69.9; (3) the end of the first sentence of the abstract has been changed to read "[...] the BNT162b2 or mRNA-1273 vaccines" rather than "[...] the BNT162b2 or mRNA-1273 -19 vaccines"
Author Information
- Christian Holm Hansen, PhD*,1,
- Astrid Blicher Schelde, PhD*,1,
- Ida Rask Moustsen-Helm, PhD1,
- Hanne-Dorthe Emborg, PhD1,
- Tyra Grove Krause, PhD2,
- Kåre Mølbak2, DMSc,
- Palle Valentiner-Branth, PhD1,# and
- on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut
- 1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- 2Epidemiological Infectious Diseases Preparedness Statens Serum Institut, Copenhagen, Denmark
- ↵#Correspondence:
Palle Valentiner-Branth, Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark, pvb{at}ssi.dk
↵* contributed equally